TrialHaematologica2017
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
Vikas Gupta et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
57 papers cite it
this papertrialcites it
TrialHaematologica2017
Vikas Gupta et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.